UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical, a leader in physician-dispensed skincare, has partnered with Alpha Aesthetic Partners to launch the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. This collaboration aims to generate real-world evidence showcasing the effectiveness of Obagi® saypha® MagIQ™, the first FDA-approved injectable hyaluronic acid filler developed using proprietary MACRO Core Technology. The joint effort underscores both parties' dedication to advancing aesthetic medicine through innovative approaches and high-quality patient care.
Alpha Aesthetic Partners, recognized for its commitment to education and collaboration in aesthetic practices, will conduct a structured, multi-site evaluation of the saypha® MagIQ™ filler within its extensive network. The ALOHA Program is designed to assess clinical performance and enhance patient experiences by implementing comprehensive Obagi protocols, thus deepening patient-provider relationships and promoting consistent, positive outcomes.
The insights gained from standardized data collected across participating practices will be shared at industry conferences and presented at the upcoming Alpha Summit. This strategy highlights the tangible impact of integrating new injectable products into clinical settings.
Drew Fine, U.S. General Manager for the Professional Channel at Obagi, emphasized that partnering with Alpha reflects Obagi's commitment to launching cosmetic solutions that generate significant real-world evidence. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi has a rich history of addressing various skin concerns, reinforcing its industry leadership.
In summary, the collaboration between Obagi Medical and Alpha Aesthetic Partners signifies a strategic initiative designed to enhance aesthetic practices through evidence-based approaches, ultimately aiming to improve patient satisfaction and clinical success in the rapidly evolving field of aesthetic medicine.
MWN-AI** Analysis
The collaboration between Obagi Medical and Alpha Aesthetic Partners through the ALOHA Program presents a significant opportunity for investors to consider. This partnership seeks to generate real-world evidence for Obagi’s first FDA-approved injectable hyaluronic acid filler, saypha® MagIQ™, which could enhance market penetration in the burgeoning aesthetic medicine sector.
Given the expected impact of the ALOHA Program, investors should observe several key factors. First, the rising demand for minimally invasive cosmetic procedures is driving growth in the aesthetic market, expected to reach over $13 billion by 2027. With Obagi’s reputation as a leading skincare innovator, combined with Alpha’s commitment to quality care and innovation, this partnership aligns strategically with market trends.
Moreover, standardized data collection across Alpha’s multi-site practices could provide crucial insights into clinical performance and patient satisfaction. These findings, to be presented at industry conferences, can establish Obagi's credibility and increase market share, appealing to both consumers and medical practitioners. Investors should evaluate how this data may attract new business and enhance Obagi’s competitive positioning.
Waldencast plc, Obagi's parent company, and its focus on scalable beauty brands may further support long-term growth. The operational efficiencies and expertise gained from this partnership can position Obagi to quickly adapt to changing market dynamics and consumer preferences, insuring against potential downturns within the category.
Lastly, as regulatory scrutiny continues to shape the aesthetic and pharmaceutical sectors, Obagi's proactive approach to generating real-world clinical evidence through this innovative partnership can mitigate risks and enhance investor confidence.
In summary, stakeholders should keep a close eye on the developments from this collaboration, as its outcomes could translate to significant market value and sustained growth for Obagi Medical within the aesthetics industry. Potential investors may find this an opportune time to consider positions in Waldencast as they capitalize on this promising initiative.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and SACRAMENTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced that it has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program. Alpha was selected as an ALOHA launch partner for its demonstrated commitment to innovation, education, collaboration, and advancing aesthetic medicine through scalable, high-quality care models.
Through this real-world evaluation collaboration, Alpha will conduct a structured, multi-site evaluation of Obagi® saypha® MagIQ™ across its network of practices. The program will leverage Alpha’s strengths in systematic education, patient satisfaction, and cross-practice culture to generate real-world evidence demonstrating the value of integrating Obagi’s first FDA-approved injectable hyaluronic acid filler into diverse clinical environments.
“At Alpha, we’re focused on building capabilities and partnerships that meaningfully support our practices,” said John Wheeler, CEO of Alpha Aesthetics Partners. “What stood out about Obagi’s approach was the emphasis on real-world data and a thoughtful look at how skincare and injectables can work together to drive better outcomes for patients and providers.”
The ALOHA Program is designed to evaluate both clinical performance and patient experience, while supporting providers with complete Obagi protocols aimed at deepening patient relationships and driving consistent, high-quality outcomes. Standardized data will be collected across participating Alpha practices, with initial findings scheduled to be presented at the upcoming Alpha Summit. Results will also be shared at key industry conferences to highlight the real-world impact of introducing a new injectable across a leading network of aesthetic practices.
"Partnering with an innovative leader like Alpha underscores Obagi’s commitment to launching new aesthetics solutions grounded in meaningful real-world evidence,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA collaboration with Alpha brings together strong clinical leadership, operational excellence, and a shared focus on elevating patient care.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com/.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand’s website, https://www.obagi.com.
About Alpha Aesthetics Partners
?Founded in 2023, Alpha Aesthetics Partners aims to advance the medical aesthetics industry through best-in-class partner support and clinical training. With a vision to build the best operating and biggest network of medical aesthetics practices in the nation, Alpha Aesthetics Partners focuses on making medical spa ownership simpler and more collaborative, allowing partners to concentrate on providing world-class patient care. The company is a portfolio company of Thurston Group, with a rapidly growing presence across 31 locations in 12 states.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
- Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
- *Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does the partnership between Obagi Medical and Alpha Aesthetic Partners align with Waldencast Acquisition Corp. WALD's strategy to enhance its brand portfolio in the aesthetics market?
What specific metrics will the ALOHA Program utilize to evaluate the effectiveness of Obagi's saypha® MagIQ™ filler and how does that relate to Waldencast Acquisition Corp. WALD's commitment to data-driven decision-making?
In what ways can the collaboration between Obagi Medical and Alpha Aesthetic Partners contribute to the expansion of Waldencast Acquisition Corp. WALD's presence in the aesthetics industry across the U.S.?
How do the innovative technologies behind Obagi’s hyaluronic acid filler influence future product development goals for Waldencast Acquisition Corp. WALD within the skincare and aesthetics sectors?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
3.9% G/L:
$1.60 Last:
8,798 Volume:
$1.56 Open:
